2018 | 2017 | 2016 | 2015 | 2014

La Jolla Pharmaceutical Company Announces LJPC-401 Presentations at 23rd Congress of the European Hematology Association

05/17/18

SAN DIEGO, May 17, 2018 (GLOBE NEWSWIRE) -- La Jolla Pharmaceutical Company (Nasdaq:LJPC), a leader in the discovery, development and commercialization of innovative therapies intended to significantly improve outcomes in patients suffering from li

Read More

La Jolla Pharmaceutical Company Announces $125 Million Royalty Financing Agreement with HealthCare Royalty Partners

05/10/18

SAN DIEGO, May 10, 2018 (GLOBE NEWSWIRE) -- La Jolla Pharmaceutical Company (Nasdaq:LJPC) (La Jolla), a leader in the discovery, development and commercialization of innovative therapies intended to significantly improve outcomes in patients suffer

Read More

La Jolla Pharmaceutical Company Announces Financial Results for the Three Months Ended March 31, 2018 and Recent Corporate Progress

05/10/18

SAN DIEGO, May 10, 2018 (GLOBE NEWSWIRE) -- La Jolla Pharmaceutical Company (Nasdaq:LJPC), a leader in the discovery, development and commercialization of innovative therapies intended to significantly improve outcomes in patients suffering from li

Read More

La Jolla Pharmaceutical Company Announces Launch of GIAPREZA™ (angiotensin II) in the United States

03/22/18

SAN DIEGO, March 22, 2018 (GLOBE NEWSWIRE) -- La Jolla Pharmaceutical Company (Nasdaq:LJPC) today announced that GIAPREZA™ (angiotensin II), injection for intravenous infusion, is now commercially available. In December 2017, GIAPREZA was approved

Read More

La Jolla Pharmaceutical Company Announces Pricing of Public Offering of Common Stock

03/15/18

SAN DIEGO, March 15, 2018 (GLOBE NEWSWIRE) -- La Jolla Pharmaceutical Company (Nasdaq:LJPC) (La Jolla), a leader in the development of innovative therapies intended to significantly improve outcomes in patients suffering from life-threatening disea

Read More

La Jolla Pharmaceutical Company Announces $100 Million Public Offering of Common Stock

03/14/18

SAN DIEGO, March 14, 2018 (GLOBE NEWSWIRE) -- La Jolla Pharmaceutical Company (Nasdaq:LJPC) (La Jolla), a leader in the development of innovative therapies intended to significantly improve outcomes in patients suffering from life-threatening disea

Read More

GIAPREZA™ (angiotensin II) Significantly Improved Survival and Reduced Time on Renal Replacement Therapy in Patients with Acute Kidney Injury

03/06/18

Analyses to Be Presented in Oral and Poster Sessions at The 23rd International Conference on Advances in Critical Care Nephrology AKI & CRRT 2018 Manuscript Published Online in Critical Care Medicine SAN DIEGO, March 06, 2018 (GLOBE NEWSWIRE

Read More

GIAPREZA™ (angiotensin II) Significantly Improved Survival of Patients with High APACHE II Scores in ATHOS-3 Study

02/25/18

Analysis to Be Presented in Oral Session at the Society of Critical Care Medicine’s 47th Critical Care Congress SAN DIEGO, Feb. 25, 2018 (GLOBE NEWSWIRE) -- La Jolla Pharmaceutical Company (Nasdaq:LJPC) today announced that an abstract, entitled “

Read More

La Jolla Pharmaceutical Company Announces Financial Results for the Three and Twelve Months Ended December 31, 2017 and Recent Corporate Progress

02/22/18

SAN DIEGO, Calif., Feb. 22, 2018 (GLOBE NEWSWIRE) -- La Jolla Pharmaceutical Company (Nasdaq:LJPC), a leader in the development of innovative therapies intended to significantly improve outcomes in patients suffering from life-threatening diseases,

Read More

La Jolla Pharmaceutical Company Announces the Treatment of First Patient in GIAPREZA™ (angiotensin II) Pediatric Study

02/21/18

SAN DIEGO, Feb. 21, 2018 (GLOBE NEWSWIRE) -- La Jolla Pharmaceutical Company (Nasdaq:LJPC) today announced that the first pediatric patient has been treated in LJ501-CRH02, La Jolla’s open-label study of GIAPREZATM (angiotensin II), injection for i

Read More



Print Page Print PageE-mail Page E-mail PageRSS Feeds RSS FeedsE-mail Alerts E-mail AlertsIR Contacts IR Contacts